Last reviewed · How we verify
Primary hemophagocytic lymphohistiocytosis — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Gamifant | EMAPALUMAB | Novimmune S.A. | Interferon gamma Blocker [EPC] | Interferon gamma | 2018-01-01 | |
| Emapalumab-Lzsg | Emapalumab-Lzsg | Swedish Orphan Biovitrum | Interferon gamma Blocker [EPC] | Interferon gamma |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Novimmune S.A. · 1 drug in Primary hemophagocytic lymphohistiocytosis
- Swedish Orphan Biovitrum · 1 drug in Primary hemophagocytic lymphohistiocytosis
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Primary hemophagocytic lymphohistiocytosis:
- Primary hemophagocytic lymphohistiocytosis treatment updates — RSS
- Primary hemophagocytic lymphohistiocytosis treatment updates — Atom
- Primary hemophagocytic lymphohistiocytosis treatment updates — JSON
Cite this brief
Drug Landscape (2026). Primary hemophagocytic lymphohistiocytosis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/primary-hemophagocytic-lymphohistiocytosis. Accessed 2026-06-10.
Related
- Primary hemophagocytic lymphohistiocytosis full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing